Wednesday, January 30, 2019

Market Outlook: Strategies To Conquer A Bear Market

Summary
A bear market can be your worst enemy or your best friend.
There are three approaches that you can employ to potentially capture enormous profit in this down market.
Which strategies you should take is strongly dependent on your own financial situation and temperament.
For indeed, the investor’s chief problem – and even his worst enemy – is likely to be himself. - Benjamin Graham
Most investors are highly enthusiastic when their stocks appreciate: nearly all investors can relate to that “warm feeling” when their portfolio lit up green during a bull market. Nevertheless, one has to conquer the bears in the middle a downturn in order to capture the profits of the subsequent bull market. In the thick of the recent downturn, the highly powerful human emotion that is fear exerts its detrimental effects. As investors do not easily forget the pain associated with blood spilling on Wall Street, fear usually induces investors to make impulsive decisions. That being said, we’d like to introduce the new Market Outlook series to help you navigate this time of uncertainty and high volatility.
As shown in Figure 1, all major market indices - NASDAQ Biotechnology Index (NASDAQ:NBI), SPDR S&P Biotech (NYSE:XBI), and Dow Jones Industrial Average (NYSE:DJI) - are trading on a downtrend. Back in 2018, we forecasted that the bear market will grow stronger in 2019. Interestingly, the bears came out of the woodwork after a brief rally in January this year. Except for a few trend breakers, most of the bioscience equities gave up a significant percentage of their recent gains. In our view, it’s quite likely that an overall negative sentiment has recently seized the market.
Figure 1: Macromarket analytics (Source: Yahoo finance)
Amid the aforesaid pessimism, there are three strategies for investors to leverage. First, you sell all your shares now to repurchase later at a potentially lower valuation. Second, you continue to hold your stocks as part of the passive investment approach. Third, you concurrently keep your shares while purchasing additional stakes in your favorite equities. Whether you make big bucks on any one of the three approaches depend on your own temperament, situation, level of research, and a bit of luck. Yes, we said it, luck! Regardless of whether you admit it, there is an element of luck when it comes to investing.

... the complete article is available at Integrated BioSci Investing

Housekeeping

Thanks for reading! To get the latest articles, please hit the orange “Follow” button on top.
Be sure to check out our private investment research community, Integrated BioSci Investing.
Dr. Tran's analyses are the best in the biotech sphere, well worth the price of subscription.
Very professional, extremely knowledgeable and very honest … I would highly recommend this service and his stock picks have been very profitable.
Simply put, this is worth every penny. Just earlier today, one of the companies recommended by Dr. Tran got acquired for a nice 50% premium.
Click here for a FREE TRIAL.
Disclaimer: As a medical doctor/market expert, Dr. Tran is not a registered investment advisor. Despite that we strive to provide the most accurate information, we neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. We reserve the right to make any investment decision for ourselves and our affiliates pertaining to any security without notification except where it is required by law. We are also NOT responsible for the action of our affiliates. The thesis that we presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. Our articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstance are individualized.

Sunday, January 27, 2019

BioLife Solutions: An IBI Notable Community Discussion On January 25, 2019

Summary
Our Notable Community Discussion helped uncovered another potential big winner, BioLife Solutions.
BioLife Solution is a logistics provider for CAR-T and cell-based therapy innovation.
As CAR-T grows increasingly prominent, we expect that BioLife to enjoy much more robust profits.
Statement from the FDA is a good sign that the company, as well as other CAR-T innovators, will enjoy the upcoming industry tailwinds.
We appreciate the intelligence from bdymnsould and especially Stockfan1 that helped us learned about this company. We wish to share this discussion with all members.
Someone’s sitting in the shade today because someone planted a tree a long time ago. - Warren Buffett
We’d like to continue the weekend coverage with another Notable Community Discussion (“NCD”) article. The initial NCD article was on ResMed. As we stated in that article, the objective of this publication series is to provide additional context to the ongoing community discussion as well as to provide coverage for members who are unable to attend our daily discussion. In this piece, we’d like to present the market intelligence relating to BioLife Solution(NASDAQ:BLFS).
Figure 1: BioLife stock chart (Source: StockCharts)

About The Company

Based in Bothell Washington, BioLife Solution is an industry leader that focuses on the development and commercialization of logistics to service the innovators of cell and gene-based therapy like CAR-T. The company is powering by the proprietary hypothermic storage and cryopreservation freeze media. These biotechnologies maintain live cellular specimen in an environment that are protected by cold temperature and other excellent preservation materials.
Specifically, the HypoThermosol and CryoStor platforms are invaluable tools that has application in regenerative medicine, biobanking, and drug discovery. The biopreservation media is differentiated because it is pure and free from potential contaminants like proteins. The enhanced purity prevents samples from potential damage while improving their self-life and survivability. All that mentioned, we’ll dive into the insight shared by the financial guru and professor, bdymnsoul.
Bdymnsoul: BioLife is an interesting company you may want to take a look at. The customers use “BioLife's CryoStor cell freeze media and HypoThermosol cell storage and shipping media to preserve starting and source material such as apheresis collections and tumor biopsies, as well as for manufactured cell and gene therapies.”
Back on Jan. 22, 2018, Biolife issued a press release stating that the company would benefit from a recent statement made by the US FDA. Responding to a growing wave of cell and gene-based therapy innovation, the FDA is showing its encouragement and support. As follow, the agency made the following projections:
Based on a surge of cell and gene therapy products entering early development, we anticipate that by 2020 we will be receiving more than 200 INDs per year, building upon our total of more than 800 active cell-based or directly administered gene therapy INDs currently on file with the FDA …by 2025, we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year based on an assessment of the current pipeline and the clinical success rates of these products.
As one of IBI’s community key opinion leader, we value bydmnsoul’s perspective and market intelligence. The Ph.D. in finance and professor shared with the IBI community, CEO Mike Rice’s comment pertaining to the FDA,
We welcome this supportive statement from the FDA regarding new policies to advance development of safe and effective cell and gene therapies. To date, we believe our optimized CryoStor and HypoThermosol proprietary biopreservation media products have been used in more than 300 customer clinical applications. The new FDA guidance could help accelerate adoption of our products specifically with later-phase companies that still use non-optimized, generic 'home-brew' preservation media cocktails. We see the potential to convert these trial sponsors to our products.
Bdymnsoul: The FDA statement which Mr. Rice refers, relates to the FDA beefing up staffing in the cell and gene therapy area.
As a prominent key opinion leader, Stockfan1 usually likes to shares perspective from other analysts. From his generosity, Stockfan1 has contributed many excellent stock tips to the community. His insight and market intelligence is stellar in our view.
Stockfan1: I like BioLife. Partnership with SAVSU is a plus. Look at their list of customers.
Figure 2: Customers using BioLife technology (Source: BioLife Investor Presentation)
Interestingly, the Maxim Group analyst (Jason McCarthy) recently raised the price target (“PT”) on BioLife from $18.00 to $26.00. And, Stockfan1 mentioned a quote from the Street Insider article re Mr. McCarthy’s assertion,
Stockfan1: “Maxim valuation continues to rise, in line with our thesis that Biolife is the tangential play to a rapidly growing cell therapy space. Important in our view is that once an efficacious cell therapy, even at the preclinical stage, is using a particular media (i.e. Biolife's) and is progressing, the last thing one wants to do is change to a new media. As such, BioLife becomes "sticky" to that cell therapy, from preclinical to commercial, which is what should drive long-term growth.”
Stockfan1: Perceptive Advisors added 29K shares!
Founded in 1999 by Joseph Edelman, Perceptive Advisors is a hedge fund based in New York City, New York. The fund is leveraging the investing prowess of the Chief Investment Officer, Adam Stone. With an excellent track record, Perceptive has grown its asset under management to the gargantuan $4.3B.
The fact that Perceptive is taking an interest in BioLife signifies that BioLife is worth further consideration by bioscience investors. After all, one of the best funds in this business like what they saw. It’s also important for investors to note that Perceptive invested in 143 companies. Therefore, it could simply mean that BioLife is one of the many stocks diversifications.
Stockfan1: I spoke to Roderick de Greef by email in September and BioLife may choose to exercise its option on SAVSU and he believes it will be accretive.
Dr. Tran: To put things into proper perspective, Roderick de Greef is the Chief Financial Officer (“CFO”) of BioLife. Thanks for sharing the excellent info with the community. If you can give more context on Savsu that’ll be great.
We believe that it is a good sign BioLife is investor friendly and transparent. A friendly and transparent management signifies leadership that works for the benefits of shareholders. And, having an excellent management is one of the requisites to a successful bioscience investment. We noted in an IBI Educational Series article,
In other lines of business, a mediocre management can still deliver value to the company. Those businesses are more straightforward and have easy operations. In contrast, bioscience investment is another beast. It requires “the cream of the crops” management to be successful. To this date, we have yet to witness a company (even with good medicines) performed satisfactorily in the long haul when the management is subpar.
Stockfan1: (Shared links to the latest investor presentation)
Dr. Tran: To make sure I don't let my personal bias prevents me from learning about great companies, I went through the presentation that you shared and noticed that SAVSU provides the technology to protect the biological specimen in a temperature controlled environment for their shipping. In my view, the company’s business operations are similar to those of CryoPort(NASDAQ:CYRX) ...
Back on Sep. 05, 2018, BioLife disclosed that the company invested $5M to increase its stakes in SAVSU from 31% to 44%. SAVSU will employ the capital to scale up its operations and inventory. This is to support the strong demand for its “evo Dry Vapor Shippers” and other technologies.
As a 7-year old company, SAVSU Technologies is headquartered in Albuquerque New Mexico. The firm builds hardware and softwares to protect live cell therapies in their transport and storage. Some clients using SAVSU include other gene therapy innovators, specialty couriers, research institution, and government.
That being said, we believe the increased ownership in SAVSU, a company that is riding on the wave of cell-based therapy (i.e. CAR-T), is quite prudent. And, it can potentially pay off big in the coming years.
Figure 3: Evo smart shippers (Source: SAVSU)
In September 2018 SAVSU announcement, BioLife also disclosed that it has an 18-month option to purchase the remaining 56% in SAVSU for $23M which is payable in the form of common stocks. If the acquisition will occur, we believe that it’ll substantially improve the prospects for BioLife. We applaud Stockfan1 for going the distance in using Philip Fisher’s scuttlebutt method to ask the company for further insight. The views from the CEO (Mike Rice) also support an upcoming SAVSU complete acquisition.
This additional investment in SAVSU supports our previously announced growth strategy to invest in companies and technologies that also supply the cell and gene therapy industry with innovative, highly valued solutions. We believe SAVSU is at an inflection point in product adoption in the cell and gene therapy market. The purchase option provides BioLife with complete flexibility with regard to a full acquisition of SAVSU, while setting a value today. Our decision to exercise the purchase option will be based on SAVSU’s continued revenue growth, and determining the optimal time to consolidate SAVSU and BioLife's financial results.

Potential Risks

As with any investment, there are pertinent risks risk that investors should be aware of. At this stage in its growth cycle, we believe that BioLife might grow too aggressively and thus encounters a potential cash flow constraint. Therefore, investors need to carefully monitor the OpEx versus the cash position to gauge any potential funding issues. The other risk is the strong competition from the other operators in the space like CryoPort. As the rule of thumb, increasing competition will translate into lower profit margins for all players.

Final Remarks

In all, we appreciate the market intelligence from bdymnsoul and Stockfan1 that helped us overcome our personal bias. The community discussion enabled us to see beyond our blind spot, as we seek to uncover potential big winners. While we will conduct further due diligence on the company, we encourage investors to take a serious look at BioLife. As a firm that is riding on the wave of medical innovation in CAR-T and other cell-based therapies, BioLife is most likely to bank in greater profits as CAR-T gains increasing prominence. Due to its stellar efficacy and safety, we believe that many good days are ahead for CAR-T and BioLife.
We’re honored that you visited us today. Founded by Dr. Hung Tran, MD, MS, CNPR, IBI is uncovering big winners like KITE, JUNO, and CORI that got acquired. While uninformed investors fear a bear market, we’re seizing this opportunity. Our secret sauce is extreme due diligence with expert data analysis. The service features daily research/consulting. Though we publish some ideas publicly, those articles are available in advance and are discussed extensively in IBI. We also reserve our best ideas exclusively for members. And, we invite you to subscribe now to lock in the current price.

Monday, December 24, 2018

IBI Research On Industry Trends: Companion Diagnostics, Companion Biomarkers, And Liquid Biopsy To Power Precision Medicine

Summary
Individualized medicine is a new trend in medical management that has improved treatment outcomes.
Companion biomarkers and companion diagnostics are powering the aforesaid precision medicine.
As a tool associated with companion biomarkers and companion diagnostics, liquid biopsy is playing increasingly prominent roles over the traditional biopsy.
By 2022, the market for liquid biopsy and companion diagnostics are expected to grow to $17B and $6.5B, respectively.
We present an overview of this new industry trend in assisting readers to make your investment decision.
I never attempt to make money on the stock market. I buy on the assumption that they could close the market the next day and not reopen it for five years. - Warren Buffett
Image source: PosterWall.com
Author's notes: In the spirit of the holiday, we'd like to share with all readers this research. If you wish to learn more about the specific companies that we mentioned in this article, we invite you to check out our private investment community, Integrated BioSci Investing.
As the Holiday is approaching, we’d like to share with all readers our Holiday Gift in showing our appreciation for your support. That being said, we’d like to share with you all our first Integrated BioSci Investing analysis on industry trends. As knowledge is power, we wish to empower readers with industry knowledge and novel developments. Our hope is that the market intelligence that we presented will better assist you in making your own informed investment decision. Accordingly, we’ll feature an overview of companion diagnostics, companion biomarkers, and liquid biopsy in this introductory research.

Precision Medicine

As the fundamental shift in medical management, personalized medicineentails individualized therapeutics in treating a particular disease or condition. The underlying idea is that the same drug can demonstrate distinctive responses in different patients. The unique genetic makeup from one individual versus another translates into differences in enzymatic expression and thereby confers differences in drug metabolism. By tailoring a specific medicine to a patient, the treatment outcomes are expected to be improved. That being said, we’ll assess how companion biomarkers and companion diagnostics fit into the landscape of individualized medicine.

Companion Biomarkers And Companion Diagnostics

Biomarkers are substances measured in the body which indicate the disease status. Despite that they are simply indicators of disease status, biomarkerscan give important clues to disease progression, treatment response, and prognosis. One can view of companion biomarkers as traffic lights that signal incoming traffic. As precision medicine, biomarkers offer critical information to bioscience innovators to assist them in developing companion diagnostics: these are prescribed in conjunction with a therapeutic regimen. Consequently, companion diagnostics and biomarkers lead to improved treatment outcomes while limiting toxicities. Ultimately, we believe that companion biomarkers and companion diagnostics will play increasingly prominent roles in the management of many diseases, especially cancers.

Screening And Confirmation Diagnostics

As mentioned, companion diagnostics and companion biomarkers play critical roles in individualized medicine. To provide further context, we’ll assess how these diagnostics fit into the overall disease management. In the diagnosis stage, physicians usually employed diagnostic agents, including screening as well as confirmation tests. As the initial diagnostic, a good screening test aims to broadly capture the disease prevalence. Hence, it’s very important for a screening test to have high sensitivity (i.e. the ability to detect disease).
In the next diagnostic step, a confirmation test is employed. This test necessitates high “specificity” (i.e. the ability to accurately identify a disease). Notably, screening tests often employ liquid samples such as urine, blood, or saliva. In contrast, a confirmation test preferably employs a tissue biopsy depending on the disease or condition of interest. That being said, both companion diagnostics and companion biomarkers can fit into either the screening or confirmatory test.
In our view, getting the first step in medical management (i.e. diagnosis) right is crucial to achieving good treatment outcomes. As diagnostics biomarkers and diagnostic companion provide crucial intelligence about the patient’s specific disease, they ensure that the best treatment is being utilized. Specifically, these diagnostics offer physicians the insight on which therapeutics are highly likely to deliver the best response. This minimizes the “trial and error” in the disease management and thus leads to improved efficacy while lower toxicity. By deterring unnecessary therapeutics and procedures, companion agents also reduce treatment expenses and expedite recovery

Diagnosis Via Liquid Biopsy

Traditionally, most confirmatory tests employ a tissue biopsy. Interestingly, the trend is shifting away from employing tissue biopsies as more bioscience companies are innovating what is known as a liquid biopsy. The aforesaid technology leverages on company biomarkers analysis via blood samples to improve the diagnostic sensitivity and specificity. In powering many companion biomarkers and companion diagnostics, a liquid biopsy expedites the diagnosis time, lowering the costs, and improving treatment outcomes, as we mentioned.
According to Market Research Future, the global liquid biopsy market is currently valued at $3.9B. And, it is forecasted to grow at the 28% compound annual growth rate (“CAGR”) to reach $17.3B by 2022. Furthermore, the companion diagnostics segment will achieve $6.5B, growing at the 20% CAGR for the same period of analysis.

Investment Opportunities

We believe that the same evolutionary pressure applies to the market as well as it applies to natural selection. With the aforementioned new trend, prudent companies are positioning themselves to profit from this fundamental shift in industry dynamics. More clinical trials are employing companion biomarkers and companion diagnostics to improve the chances of clinical trial success. These companies are using companion diagnostics and biomarkers improve treatment outcomes while delivering revenues growth.
Taken altogether, the novel industry trend, as we elucidated, will benefit both patients and investors alike. Some key firms that are aligning their corporate strategy to harness this reward include Trovagene, RaindDance Technologies, Agena Bioscience, Admera Health, Biocept, Circulogene Theranostics, Inivata, SAGA Diagnostics, Exosome Diagnostics, and etc. We also featured several companies that are tinkering with companion diagnostics such as Progenics Pharmaceuticals (NASDAQ:PGNX), Endocyte Pharmaceuticals (NASDAQ:ECYT), Spectrum Pharmaceuticals (NASDAQ:SPPI), and Guardant Health (NASDAQ:GH).

Potential Risks

Despite having key advantages, there are associated risks with liquid biopsy, and companion biomarker as well as diagnostics. In our opinion, tissue biopsy tends to show better diagnostic accuracy. There are certain cancers and conditions that are slow to manifest their disease status through biomarkers and thereby limits the usability of liquid biopsy. As with any novel development, it takes times to iron out various kinks. There are also unique risks associated with the specific companies that we mentioned which we encourage readers to check on in their corresponding research.

Final Remarks

In all, we strongly believe that liquid biopsy, companion diagnostics and companion biomarkers will continue to power the new trend of individualized or precision medicine. Companies that positioned themselves ahead of the curve will most likely reap the substantial profits for their shareholders. Clinical trials that utilize biomarkers and companion diagnostics will improve their chances of success. Furthermore, these new industry developments will alleviate the rising costs of healthcare and improve treatment outcomes for countless patients worldwide. As the final note, we hope that you enjoy this research and hope that you enjoy your Holiday weekend. Merry Christmas and A Happy New Year!
We’re honored that you visited us today. Founded by Dr. Hung Tran, MD, MS, CNPR, IBI is uncovering big winners like KITE, JUNO, and CORI that got acquired. While uninformed investors fear a bear market, we’re seizing this opportunity. Our secret sauce is extreme due diligence with expert data analysis. The service features daily research/consulting. Though we publish some ideas publicly, those articles are available in advance and are discussed extensively in IBI. We also reserve our best ideas exclusively for members. And, we invite you to subscribe now to lock in the current price.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Additional disclosure: As a medical doctor/market expert, Dr. Tran is not a registered investment advisor. Despite that we strive to provide the most accurate information, we neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. We reserve the right to make any investment decision for ourselves and our affiliates pertaining to any security without notification except where it is required by law. We are also NOT responsible for the action of our affiliates. The thesis that we presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. Our articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstance are individualized.

Saturday, September 15, 2018

More Benefits To IBI Members: New Research And Report Series To Assist Our Community

Summary

Specialty Research Series elucidates investment prospects in various markets (NASH, RNA-based medicines, CAR-T, genes therapy/editing, and infectious disease).
Educational Series explicates our investment philosophy for you to adapt to your own use.
Expert Interview Series features key opinion leaders and their best recommendations. Portfolio Review Series provides our latest takes on promising investments.
M&A Series reviews merger & acquisitions and forecasts potential outcomes. Sector Report Series analyzes industry headwinds and tailwinds.
Quality Improvement Series analyzes our mistakes to deliver better future returns. Development Series gives a sneak peek preview on our future direction.
We recently upgraded IBI with ongoing changes to improve the quality of our private research community. Accordingly, we improved our presentation on ways to best leverage on our research via a question and answer format. In this article, we’ll feature various research/report series with corresponding links to make it easy and efficient for you to conduct your own research due diligence. The aforesaid series include the following: Specialty Research, Educational, Expert Interview, M&A, Sector Report, Portfolio Review, Quality Improvement, and Development.

Specialty Research Series

We’ve featured a total of five different Specialty Research Series. The primary objective of the Specialty Research is to deliver in-depth analysis into a particular niche for investors who are interested in exploring only a particular field, for instance, the lucrative nonalcoholic steatohepatitis (“NASH”) market. Moreover, we discuss the latest medical breakthroughs in this series. Each article goes over the overall market opportunity, challenges, and investment prospects. For your convenience, we feature the links to five Specialty Research (on NASH, RNA-based medicines, CAR-T, genes therapy/editing, and infectious disease) as presented below.

Educational Series

Having a solid understanding of the what, why, when, and how pertaining to an investment is crucial for long-term success. That being said, we a good number of educational articles in the hopes that you find our investing approach useful. We recommend that you read these articles often and determine how you can adapt it to your own investment approach to improving your returns. After all, education is a lifelong journey.

Expert Interview Series

Back in 2017, we conducted several expert interviews in the efforts to increase the depth of coverage for our members. In the Expert Interview series, you can get a glimpse into the insight of different key opinion leaders (“KOLs”) and learn how they investing. You also get their top stock recommendations. For instance, we found out about Omeros Corporation (NASDAQ:OMER) via the interview with the stellar Scientist Trader, Biotech Beast.

M&A Series

The merger & acquisition (M&A) series features various aspects of an acquisition. In these articles, we analyze different criteria that are conducive to an M&A. And in leveraging our experience, we prognosticate potential M&A targets that you might want to check out

Sector Report Series

While we predominantly focus on bottom-up research on individual companies, it’s important to have an understanding of the overall bioscience sector. Knowing the associated industry tailwinds and headwinds can give an investor the edge in analyzing the particular bioscience investment. Going forward, we’ll increase our focus on the development at the FDA to give members a heads up on what the FDA Commissioner (Dr. Scott Gottlieb) has in store for patients, companies, and investors.

Portfolio Review Series

Every quarter, we conduct an in-depth analysis of our long-term portfolio (CP-Alpha). We recommend that you check our prior reviews as well as the latest article to track our progress. In the latest report, you can learn about our best ideas that can potentially deliver multiple fold profits. The prime example is Intercept Pharmaceuticals (NYSE:ICPT), a company that has the best chances of making a successful turnaround in the Q2 2018 Portfolio Review. Since our recommendation, the company has procured +60%.

Quality Improvement Series

In this series, we present an analysis of our mistakes and invaluable lessons that we learned in order to improve our research quality for IBI members.

Development Series

Our goal for the IBI Development Series is to alert investors to our upcoming developments and their progress. We are brewing various portfolio developments. Nevertheless, we are short on manpower and need your help with tracking various catalyst. Please send your message to either Dr. Tran or HopeAlpha if you wish to help out.

Final Remarks

We hope that this article (and our reorganization of various research and report into their respective series) and new pieces are helpful. The perk of being a member is that you'll have access to this article and all the links that are not available to the free site. More importantly, you'll have access to our ongoing updates. 
We’re honored that you visited us. Founded by Dr. Hung Tran, MD, MS, CNPR, IBI is delivering stellar returns. For instance, Nektar, Spectrum, Madrigal, Atara, and Kite procured +215%, +154%, +174%, +191%, and +83%, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features daily research/consulting. While we publish some ideas publicly, those articles are available in advance and discussed more extensively in IBI. We also reserve our best ideas (new 5-star stocks) exclusively for IBI members. And, we invite you to subscribe now to lock in the current price.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Additional disclosure: As a medical doctor/market expert, Dr. Tran is not a registered investment advisor. Despite that we strive to provide the most accurate information, we neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. We reserve the right to make any investment decision for ourselves and our affiliates pertaining to any security without notification except where it is required by law. We are also NOT responsible for the action of our affiliates. The thesis that we presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. Our articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized.